Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.02
VRX's Cash to Debt is ranked lower than
55% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. VRX: 0.02 )
VRX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.02

Equity to Asset 0.20
VRX's Equity to Asset is ranked lower than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. VRX: 0.20 )
VRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.85
Current: 0.2

0.18
0.85
Interest Coverage 2.10
VRX's Interest Coverage is ranked lower than
51% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. VRX: 2.10 )
VRX' s 10-Year Interest Coverage Range
Min: 0.12   Max: 121.91
Current: 2.1

0.12
121.91
F-Score: 6
Z-Score: 2.63
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.75
VRX's Operating margin (%) is ranked higher than
93% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. VRX: 24.75 )
VRX' s 10-Year Operating margin (%) Range
Min: -9.32   Max: 45.51
Current: 24.75

-9.32
45.51
Net-margin (%) 11.21
VRX's Net-margin (%) is ranked higher than
83% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. VRX: 11.21 )
VRX' s 10-Year Net-margin (%) Range
Min: -47.86   Max: 42.72
Current: 11.21

-47.86
42.72
ROE (%) 18.05
VRX's ROE (%) is ranked higher than
92% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. VRX: 18.05 )
VRX' s 10-Year ROE (%) Range
Min: -59.65   Max: 88.03
Current: 18.05

-59.65
88.03
ROA (%) 3.41
VRX's ROA (%) is ranked higher than
73% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. VRX: 3.41 )
VRX' s 10-Year ROA (%) Range
Min: -18.92   Max: 47.04
Current: 3.41

-18.92
47.04
ROC (Joel Greenblatt) (%) 78.79
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. VRX: 78.79 )
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.66   Max: 291.4
Current: 78.79

-50.66
291.4
Revenue Growth (3Y)(%) 53.40
VRX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. VRX: 53.40 )
VRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.8   Max: 82.1
Current: 53.4

-10.8
82.1
EBITDA Growth (3Y)(%) 64.00
VRX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. VRX: 64.00 )
VRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.7   Max: 113
Current: 64

-35.7
113
EPS Growth (3Y)(%) 83.10
VRX's EPS Growth (3Y)(%) is ranked higher than
98% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. VRX: 83.10 )
VRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -39.4   Max: 100.6
Current: 83.1

-39.4
100.6
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VRX Guru Trades in Q2 2014

Joel Greenblatt 6,172 sh (New)
Louis Moore Bacon 127,422 sh (+1589.05%)
Diamond Hill Capital 147,867 sh (+403.46%)
George Soros 472,187 sh (+185.46%)
Andreas Halvorsen 11,830,932 sh (+27.27%)
Chris Davis 3,153,748 sh (+16.03%)
Steve Mandel 10,089,450 sh (+14.44%)
Jean-Marie Eveillard 1,024,402 sh (+13.50%)
Lee Ainslie 2,625,014 sh (+8.39%)
Glenn Greenberg 6,050,442 sh (+8.19%)
Ruane Cunniff 34,298,384 sh (+0.24%)
Lou Simpson 1,615,549 sh (+0.06%)
Steven Cohen 1,528,606 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Jim Simons Sold Out
Mariko Gordon Sold Out
Daniel Loeb Sold Out
Pioneer Investments Sold Out
Private Capital 300,446 sh (-1.02%)
Wallace Weitz 1,551,076 sh (-2.91%)
John Paulson 500,300 sh (-49.97%)
Jeremy Grantham 45,552 sh (-70.16%)
» More
Q3 2014

VRX Guru Trades in Q3 2014

Jana Partners 1,284,184 sh (New)
Paul Tudor Jones 6,826 sh (New)
George Soros 626,748 sh (+32.73%)
Diamond Hill Capital 173,012 sh (+17.01%)
Lou Simpson 1,815,916 sh (+12.40%)
Chris Davis 3,529,237 sh (+11.91%)
Wallace Weitz 1,691,525 sh (+9.05%)
Steve Mandel 10,985,940 sh (+8.89%)
Glenn Greenberg 6,586,582 sh (+8.86%)
John Paulson 520,700 sh (+4.08%)
Ruane Cunniff 34,494,015 sh (+0.57%)
Jeff Ubben 18,923,877 sh (unchged)
Steven Cohen 523,400 sh (unchged)
Joel Greenblatt Sold Out
Private Capital 296,871 sh (-1.19%)
Jean-Marie Eveillard 1,010,802 sh (-1.33%)
Lee Ainslie 2,527,896 sh (-3.70%)
Andreas Halvorsen 9,967,690 sh (-15.75%)
Steven Cohen 1,056,700 sh (-30.87%)
Jeremy Grantham 23,705 sh (-47.96%)
Louis Moore Bacon 30,544 sh (-76.03%)
» More
Q4 2014

VRX Guru Trades in Q4 2014

Joel Greenblatt 295,632 sh (New)
Jim Simons 38,989 sh (New)
Jeremy Grantham 1,042,191 sh (+4296.50%)
Paul Tudor Jones 100,000 sh (+1364.99%)
Jana Partners 4,307,534 sh (+235.43%)
Jean-Marie Eveillard 1,191,832 sh (+17.91%)
Jeff Ubben 19,383,877 sh (+2.43%)
Jeff Ubben 19,383,877 sh (+1.30%)
Ruane Cunniff 34,331,973 sh (unchged)
John Paulson 520,700 sh (unchged)
Ruane Cunniff 34,331,973 sh (-0.47%)
Chris Davis 3,508,163 sh (-0.60%)
Diamond Hill Capital 171,513 sh (-0.87%)
Lou Simpson 1,794,227 sh (-1.19%)
Private Capital 292,802 sh (-1.37%)
George Soros 606,587 sh (-3.22%)
Lee Ainslie 2,423,766 sh (-4.12%)
Glenn Greenberg 6,126,609 sh (-6.98%)
Andreas Halvorsen 9,077,007 sh (-8.94%)
Wallace Weitz 1,378,606 sh (-18.50%)
Steve Mandel 8,250,886 sh (-24.90%)
Louis Moore Bacon 14,286 sh (-53.23%)
Steven Cohen 132,300 sh (-87.48%)
» More
2015

VRX Guru Trades in 2015

Bill Ackman 19,473,933 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Valeant Pharmaceuticals International Inc

Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc - Jul 25, 2014

We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Sequoia Fund's Discussion of Valeant Pharmaceuticals - Mar 07, 2014

Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million.



Cash earnings per share have probably more than tripled over the last four years. While we do not expect this growth trajectory to continue at such a rapid pace in the future, we do believe the company can continue to produce positive organic growth supplemented by ongoing acquisitions that will enable Valeant to grow cash earnings per share at an above-average rate.



We like Valeant’s approach to the pharmaceutical business. It has acquired a diverse stable of branded, generic and OTC drugs and, more recently, medical devices including dermal fillers and contact lenses. Many of its products are steady sellers in specialty categories like dermatology and ophthalmology. In our view, Valeant is essentially a value investor in health care products.





Source: Sequoia Fund's 2013 Annual Report - Management's Discussion of Fund Performance



Check out Sequoia Fund latest stock trades

Wallace Weitz Comments on Valeant Pharmaceuticals - Jul 15, 2013

Valeant (VRX--$86)(VRX) Valeant Pharmaceuticals continues to make acquisitions (most recently agreeing to purchase Bausch and Lomb), wring cost savings from the combined operations, and grow earnings per share. The outlook for Valeant’s well-diversified portfolio of 1,100 products is relatively predictable. The company has a robust pipeline of acquisition candidates and we expect Valeant to build on its dermatology and eye care franchises over the next few years.

From Wallace Weitz’s second quarter 2013 letter to shareholders.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Valeant Pharmaceuticals International Inc

Ruane, Cunniff & Goldfarb Inc Comments on Valeant
A topic many shareholders and clients wanted to discuss with us in 2014 was Valeant (VRX). It is the largest holding in Sequoia by far. One could argue Valeant wasted much of the year on a quixotic effort to buy Allergan (AGN), maker of Botox. Allergan had no interest in being acquired and fought a vicious and savvy public relations campaign to portray Valeant as unworthy of marriage to such a prized catch. In the end, Allergan found a suitor more to its liking in Actavis (ACT), and Actavis agreed to pay a substantially higher price than Valeant had offered. Read more...
Jeff Ubben Deals in Only Four Companies in Fourth Quarter
Jeff Ubben (Trades, Portfolio), founder, chief executive officer and chief investment officer of ValueAct Holding LP, made multiple buys and sells of stocks in just four companies in the fourth quarter. That isn’t typical. Normally, he buys and sells stocks in many companies in a quarter but usually once, rarely on multiple occasions. Read more...
Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectivity
If you don’t know Lou Simpson (Trades, Portfolio), you should. He was the former investment manager at GEICO and Warren Buffett (Trades, Portfolio) spoke highly about him many times. Mr. Simpson just reported his third quarter portfolio. He buys Liberty Global PLC, Valeant Pharmaceuticals International Inc, U.S. Bancorp, Charles Schwab Corp, Brookfield Asset Management Inc, Oracle Corporation, Wells Fargo & Co, Berkshire Hathaway Inc, Crown Holdings Inc, sells TE Connectivity Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, SQ Advisors, LLC. As of 09/30/2014, SQ Advisors, LLC owns 13 stocks with a total value of $2.6 billion. These are the details of the buys and sells. Read more...
Most Held Canadian Stocks of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc
We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 82.80
VRX's P/E(ttm) is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. VRX: 82.80 )
VRX' s 10-Year P/E(ttm) Range
Min: 5.96   Max: 666.31
Current: 82.8

5.96
666.31
Forward P/E 11.39
VRX's Forward P/E is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. VRX: 11.39 )
N/A
PE(NRI) 83.00
VRX's PE(NRI) is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. VRX: 83.00 )
VRX' s 10-Year PE(NRI) Range
Min: 5.96   Max: 642.31
Current: 83

5.96
642.31
P/B 13.71
VRX's P/B is ranked lower than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. VRX: 13.71 )
VRX' s 10-Year P/B Range
Min: 1.03   Max: 13.92
Current: 13.71

1.03
13.92
P/S 8.21
VRX's P/S is ranked higher than
51% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. VRX: 8.21 )
VRX' s 10-Year P/S Range
Min: 1.61   Max: 9.38
Current: 8.21

1.61
9.38
PFCF 41.70
VRX's PFCF is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. VRX: 41.70 )
VRX' s 10-Year PFCF Range
Min: 2.67   Max: 281.44
Current: 41.7

2.67
281.44
POCF 33.14
VRX's POCF is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. VRX: 33.14 )
VRX' s 10-Year POCF Range
Min: 4.05   Max: 48.31
Current: 33.14

4.05
48.31
EV-to-EBIT 44.16
VRX's EV-to-EBIT is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. VRX: 44.16 )
VRX' s 10-Year EV-to-EBIT Range
Min: -5795.6   Max: 2482.6
Current: 44.16

-5795.6
2482.6
PEG 1.48
VRX's PEG is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 1.48 )
VRX' s 10-Year PEG Range
Min: 0.88   Max: 703.2
Current: 1.48

0.88
703.2
Shiller P/E 3153.81
VRX's Shiller P/E is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. VRX: 3153.81 )
VRX' s 10-Year Shiller P/E Range
Min: 11.93   Max: 3175
Current: 3153.81

11.93
3175
Current Ratio 1.54
VRX's Current Ratio is ranked higher than
61% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. VRX: 1.54 )
VRX' s 10-Year Current Ratio Range
Min: 0.91   Max: 6.13
Current: 1.54

0.91
6.13
Quick Ratio 1.19
VRX's Quick Ratio is ranked higher than
61% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. VRX: 1.19 )
VRX' s 10-Year Quick Ratio Range
Min: 0.78   Max: 5.66
Current: 1.19

0.78
5.66
Days Inventory 149.69
VRX's Days Inventory is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. VRX: 149.69 )
VRX' s 10-Year Days Inventory Range
Min: 89.42   Max: 333.93
Current: 149.69

89.42
333.93
Days Sales Outstanding 94.97
VRX's Days Sales Outstanding is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. VRX: 94.97 )
VRX' s 10-Year Days Sales Outstanding Range
Min: 43.41   Max: 146.62
Current: 94.97

43.41
146.62

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 5.60
VRX's Price/DCF (Projected) is ranked higher than
77% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. VRX: 5.60 )
VRX' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 8.81
Current: 5.6

0.38
8.81
Price/Median PS Value 2.48
VRX's Price/Median PS Value is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. VRX: 2.48 )
VRX' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 5.04
Current: 2.48

0.61
5.04
Price/Peter Lynch Fair Value 3.32
VRX's Price/Peter Lynch Fair Value is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 3.32 )
VRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.95   Max: 3.91
Current: 3.32

0.95
3.91
Earnings Yield (Greenblatt) 2.30
VRX's Earnings Yield (Greenblatt) is ranked higher than
71% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. VRX: 2.30 )
VRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 20.6
Current: 2.3

0.1
20.6
Forward Rate of Return (Yacktman) 61.70
VRX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. VRX: 61.70 )
VRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 62.5
Current: 61.7

2.5
62.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany,
Valeant Pharmaceuticals International Inc was formed on 29th March, 1994 and was formerly known as Biovail Corporation. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products "OTC", and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for VRX

Headlines

Articles On GuruFocus.com
Pershing Square Holdings: First Annual Report Mar 25 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
Ruane, Cunniff & Goldfarb’s Sequoia Fund Q4 2014 Shareholder Letter Mar 16 2015 
Ruane Cunniff Sells Portions of Five of its Top 10 Stakes Mar 13 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
How Good is Your Argument? Feb 16 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 


More From Other Websites
Drugmaker Valeant completes $11 billion purchase of Salix Apr 01 2015
Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Apr 01 2015
Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Apr 01 2015
Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Apr 01 2015
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Apr 01 2015
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Apr 01 2015
Health Care: 3 Picks in a More Expensive Sector Apr 01 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Apr 01 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Apr 01 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Apr 01 2015
Pharma's Comeback Deals Keep Drug M&A on Track to Reach Records Apr 01 2015
Charter Communications, Inc. (CHTR): Ratan Capital Group Stays Hot As Stock Soars on Bright House... Mar 31 2015
Bill Ackman maintains large exposure to health-care sector with new Valeant stake Mar 31 2015
Could the Life Time Fitness Deal Get Competitive? Mar 31 2015
Looking For Top Management? Consider These 3 Big Caps Mar 30 2015
Healthcare sector leads feverish M&A activity Mar 30 2015
Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015
13D Filings Mar 27 2015
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive... Mar 27 2015
Is Antitrust a Risk in the Life Time Fitness Merger? Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK